ESBD_File_341623_Memorandum 2 (Opioid Products; 10-25-23).pdf
PDF 127 KB Posted
- Solicitation number
- R2270-2023-7
- Issued by
- Travis County, Austin City, Texas
About this file
This document is a memorandum providing responses to questions received regarding a Request for Proposal (RFP) issued by Integral Care, a government agency in Texas, for the sale of opioid use disorder treatment medications including methadone, buprenorphine, and buprenorphine/naloxone. The RFP seeks proposals for these medications to be used in Integral Care's Narcotic Treatment Program, which serves between 450-500 patients annually. The RFP was released on November 14, 2023, and proposals are due by 5:00 p.m. CDT on December 19, 2023. Historically Underutilized Businesses, including Minority-Owned Businesses and Women-Owned Businesses, are encouraged to apply.
The memorandum addresses various questions related to the RFP, including the historical patient volume, medication purchasing and billing practices, expected future patient volume, the number and locations of treatment centers, historical purchasing patterns, and the types of medications requested. Key details clarified include that all medications are purchased directly by Integral Care and administered on-site, the RFP is specific to opioid medications (not including naloxone), and there is only one treatment center location.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| ESBD_File_341623_RFP - Opioid Products (11-14-23).docx | DOCX document | |
| ESBD_File_341623_Memorandum (Opioid Products; 10-25-23).pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
MEMORANDUM 2
TO: All Persons/Entities That Have Received Integral Care’s October 25, 2023
Request for Proposal for Opiod Substance Use Disorder Treatment Medications
(“RFP”)
FROM: Brody Ballard, Coordinator of Legal Services
RE: Responses to Questions Regarding RFP
DATE: December 6, 2023
QUESTIONS/RESPONSES
Q1: How many patients were treated under the Opioid Disorder program in 2022, 2023 YTD?
A: Integral Care’s Narcotic Treatment Program served between 450-500 patients in years
2022-2023.
Q2: What percentage of these medications are billed to prescription insurance and what percentage of these medications are purchased by Integral Care?
A: All medications are purchased by Integral Care’s Narcotic Treatment Program from an authorized distributor and seller.
Q3: Does Integral Care expect the number of patients to increase in 2024 from
2023?
A: This question does not pertain to the process or specifications of the RFP.
Q4: How many locations are designated as treatment centers? Would it be possible to share the address and patient size per center?
A: Integral Care has one (1) location for its Narcotic Treatment Program.
Q5: Can Integral Care share the purchase date from last couple of years?
A: Historically, purchases are made at intervals as supply amounts are depleted and may occur monthly or every other month as stock indicates.
Q6: Would the selected vendor be restricted to fill non-opioid medications for patients under this program?
A: Integral Care’s Narcotic Treatment Program only administers and distributes opioid medications.
Q7: Are medications being delivered/mailed to patient's home or treatment centers?
If it is the mix of both then what would be the percentage split between the two options.
A: Integral Care’s Narcotic Treatment Program is responsible for all administration and dispensing of medications directly to patients from its dedicated locations, and is not permitted to deliver or mail such medications to a patient's home.
Q8: What type of naloxone is requested? Naloxone Nasal Spray or injection?
A: Neither. The RFP is for products that include Suboxone - (i.e.
buprenorphine/naloxone combo medication).
File details come from the government source that posted it. Updated .